Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells.

Announced Tuesday, the cash infusion includes €28 million ($31.4 million) in a series B round led by LSP, as well as a €4.6 million ($5.2 million) grant from the Walloon region of Belgium and a €2 million ($2.2 million) loan from Belfius...